Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats

British Journal of Pharmacology

Volumn 161, Issue 1, 2010, Pages 92-102

  Gardiner, S M ^a   March, J E ^a   Kemp, P A ^a   Bennett, T ^a   Baker, D J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

dipeptidyl peptidase 4; glucagon like peptide 1; regional haemodynamics

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA ADRENERGIC RECEPTOR; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BOLUS INJECTION; CARDIOVASCULAR EFFECT; COMPETITIVE INHIBITION; CONSCIOUSNESS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DRUG MECHANISM; HYPERTENSION; MALE; MESENTERIC ARTERY; NERVE BLOCK; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; SPRAGUE DAWLEY RAT; TACHYCARDIA; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; MALE; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TACHYCARDIA; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 77955828386     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00867.x     Document Type: Article

References (30)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to receptors and channels (GRAC) 4th Edition. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Ban K, Noyan-Ashraf H, Hœfer J, Bolz S-S, Drucker DJ, Husain M (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 : 2340 2350.
3. Barragán JM, Rodríguez RE, Blázquez E (1994). Changes in arterial blood pressure and heart rate by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266 : E459 E466.
4. Barragán JM, Rodríguez RE, Eng J, Blázquez E (1996). Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67 : 63 68.
5. Barragán JM, Eng J, Rodríguez RE, Blázquez E (1999). Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277 : E784 E791.
6. Bojanowska E, Stempniak B (2002). Effects of glucagon-like peptide-1 (7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J Endocrinol 172 : 303 310.
7. Broadley KJ, Williamson KL, Roach AG (1999). In vivo demonstration of α-adrenoceptor-mediated positive inotropy in pithed rats: evidence that noradrenaline does not stimulate myocardial α-adrenoceptors. J Auton Pharmacol 19 : 55 63.
8. Deacon CF, Johnsen AH, Holst JJ (1995). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 : 952 957.
9. Deacon CF, Plambœck A, Møller S, Holst JJ (2002). GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 282 : E873 E879.
10. Drucker DJ, Nauck MA (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 : 1696 1705.
11. Gardiner SM, March JE, Kemp PA, Bennett T (2006a). Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 316 : 852 859.
12. Gardiner SM, March JE, Kemp PA, Bennett T (2006b). Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4. Br J Pharmacol 149 : 802 809.
13. Gardiner SM, March JE, Kemp PA, Bennett T (2008). Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol 154 : 60 71.
14. ATP and cAMP. Arch Biochem Biophys 478 : 136 142.
15. Grieve DJ, Cassidy RS, Green BD (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157 : 1340 1351.
16. Jax T (2009). Treatment of patients with diabetes with GLP-1 analogues or DPP-4-inhibitors: a hot topic for cardiologists? Clin Res Cardiol 98 : 75 79.
17. Kieffer TJ, Habener JF (1999). The glucagon-like peptides. Endocr Rev 20 : 876 913.
18. Knudsen LB, Pridal L (1996). Glucagon-like peptide-1(9-36) amide is a major metabolite of glucagon-like peptide-1(7-36) after in vivo administration in dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318 : 429 435.
19. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, Deacon CF et al. (2006). The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 290 : E1118 E1123.
20. Nielsen LL (2005). Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10 : 703 710.
21. Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 : H2401 H2408.
22. Ossum A, van Deurs U, Engstrøm T, Jensen JS, Treiman M (2009). The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 60 : 411 417.
23. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R et al. (2001). Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53 : 260 267. (Pubitemid 33029654)
24. Sauvé M, Ban K, Momen A, Zhou Y-Q, Henkelman RM, Husain M et al. (2010). Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes 59 : 1063 1073.
25. Sonne DP, Engstrøm T, Trieman M (2008). Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146 : 243 249.
26. Theodorsson-Norheim E (1987). Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med 17 : 85 99.
27. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Allessio DA (2003). Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88 : 1772 1779.
28. Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, Gardiner SM (2004). Acute cardiovascular effects of sibutramine in conscious rats. J Pharmacol Exp Ther 308 : 1102 1110.
29. Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD et al. (2006). cis-2,5-Dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization. J Med Chem 49 : 3068 3076.
30. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME et al. (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 : 43 52.